ACBD7

Across TCGA pan-cancer cohorts, ACBD7 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ACBD7’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ACBD7 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ACBD7 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

LSCC, HNSC, and LUAD are the cancer types where ACBD7 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACBD7 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.428	.001	4	view →
HNSC	All	II,III,IV	−0.342	.012	4	view →
LUAD	All	All	+0.349	<.001	3	view →
PDAC	Female	All	−0.826	.032	2	view →
OV	All	All	+0.662	.033	2	view →
CCRCC	All	II,III,IV	−0.377	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ACBD7–LSCC

Open the LSCC breakdown →